Lenvatinib, a multitargeted kinase inhibitor of FGFR1–4, VEGFR1-3, KIT, RET, and PDGFR-β,4 has been proven effective for liver and thyroid cancers. This evidence concerns the gene KIT and thyroid gland carcinoma.